The global paroxetine hydrochloride market is expected to rise at a considerable CAGR during the forecast period (2022-2028). Paroxetine is a drug that is used to treat social mental problems, serious depression, anxiety disorders, panic attacks, and, among other things. the increasing prevalence of mental health disorders and the rising awareness about mental health among people is the major factor driving the market growth. As per WHO, depression is a common illness worldwide, with an estimated 3.8% of the population affected, including 5.0% among adults and 5.7% among adults older than 60 years. Moreover, over 700 000 people die due to suicide every year. Suicide is the fourth leading cause of death in 15-29-year-olds. Due to increasing depression among population, the demand for anti-depression drugs such as paroxetine hydrochloride is also increasing, thereby driving the market growth.
Browse the full report description of “Global Paroxetine Hydrochloride Market Size, Share and Trends Analysis Report by Type (Purity: 98% -99% and Purity: above 99%), by Application (OCD Treatment, Anxiety Treatment, Others) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/paroxetine-hydrochloride-market
Moreover, market players are also aiding in market growth by new product launches. For instance, GlaxoSmithKline plc has announced the launch of its antidepressant Paxil CR Tablets 12.5mg and Paxil CR Tablets 25mg (paroxetine hydrochloride hydrate, hereinafter referred to as Paxil CR Tablets, CR stands for Controlled Release). Paxil CR tablets are the first controlled-release version of Paxil tablets, an antidepressant that is an SSRI (selective serotonin reuptake inhibitor).
Besides, Maiden Pharmaceuticals ltd. has launched Madotine (30 mg) that is a selective serotonin reuptake inhibitor (SSRI) antidepressant used to treat major depression, obsessive-compulsive disorder, panic disorder, social anxiety, and generalized anxiety disorder. It raises serotonin levels in the brain, a natural molecule that aids in mental equilibrium.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
Competitive Landscape- GlaxoSmithKline plc, Merck KGaA, Sun Pharmaceutical Industries Ltd., Apotex Inc., Sebela Pharmaceuticals, Inc., and others.
Key questions addressed by the report
• What is the market growth rate?
• That segment and region dominate the market in the base year?
• That segment and region will project the fastest growth in the market?
• How does COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Paroxetine Hydrochloride Market Report by Segment
By Type
By Application
Global Paroxetine Hydrochloride Market Report Segment by Region
North America
• US
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East and Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/paroxetine-hydrochloride-market